Castration-resistant Prostate Cancer Clinical Trials in Beijing, Beijing Municipality
13 recruitingBeijing, Beijing Municipality, China
Showing 1–13 of 13 trials
Recruiting
Phase 3
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Metastatic Castration-resistant Prostate Cancer
Pfizer900 enrolled240 locationsNCT06629779
Recruiting
Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled329 locationsNCT06136650
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
Advanced Metastatic Castration-resistant Prostate Cancer
Shenzhen Ionova Life Sciences Co., Ltd.84 enrolled22 locationsNCT06609005
Recruiting
Phase 1
A Phase I Trial of A-CAR032 in Participants With mCRPC
Prostate CancerMetastatic Castration-resistant Prostate Cancer
Shanghai AbelZeta Ltd.27 enrolled5 locationsNCT07344311
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Celgene960 enrolled282 locationsNCT06764485
Recruiting
Phase 2
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Locally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer
Pfizer320 enrolled44 locationsNCT04606446
Recruiting
Phase 1
A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer
Prostate CancerMetastatic Castration-resistant Prostate CancerMetastatic Hormone Sensitive Prostate Cancer
Astellas Pharma Global Development, Inc.12 enrolled1 locationNCT07339267
Recruiting
Early Phase 1
Study of Allogeneic Anti-PSMA CAR-NK Cell for Metastatic Castration-Resistant Prostate Cancer
Prostate Cancer Castration-resistant Prostate Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences10 enrolled1 locationNCT07156045
Recruiting
Phase 1Phase 2
A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients
Metastatic Castration-resistant Prostate Cancer
Hinova Pharmaceuticals Inc.84 enrolled27 locationsNCT06155084
Recruiting
Early Phase 1
177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital30 enrolled1 locationNCT05603559
Recruiting
Phase 2
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
Metastatic Castration-resistant Prostate Cancer (mCRPC)
MediLink Therapeutics (Suzhou) Co., Ltd.100 enrolled24 locationsNCT06241846
Recruiting
Not Applicable
177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital9 enrolled1 locationNCT05613738
Recruiting
Phase 2
Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer
Castration-resistant Prostate Cancer
RemeGen Co., Ltd.40 enrolled3 locationsNCT06227156